Description
Glimepiride is a second generation sulfonylurea that exhibits anti-diabetic activity. Glimepiride inhibits ATP-dependent K+ channels in β cells, forcing cells to remain depolarized, increasing Ca2+ influx and insulin secretion. Glimepiride also exhibits neuroprotective benefit, decreasing expression and activity of BACE1 and amyloid-β (Aβ) in neurons in a PPARγ-dependent manner.
References
Liu F, Wang Y, Yan M, et al. Glimepiride attenuates Aβ production via suppressing BACE1 activity in cortical neurons. Neurosci Lett. 2013 Dec 17;557 Pt B:90-4. PMID: 24184877.
Bashir MI, Pathan MF, Raza SA, et al. Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan. Indian J Endocrinol Metab. 2012 Jul;16(4):503-7. PMID: 22837904.
Abdelmoneim AS, Hasenbank SE, Seubert JM, et al. Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes Metab. 2012 Feb;14(2):130-8. PMID: 21923736.